EUCTR2006-004177-95-DK进行中（未招募）不适用
A single center, randomized, partially blind, placebocontrolled, crossover, single oral dose study to assess theeffect of concomitant antacid (calcium carbonate) on thepharmacokinetics and pharmacodynamics of SMC021 (0.8mg salmon calcitonin/200 mg 5-CNAC) in healthypostmenopausal women
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Female volunteers between the ages of 40 and 70 years with a weight at least 50 kg and a BMI of 18-30, at least 5 years after natural menopause or 6 months after surgical menopause. Menopause will be confirmed by plasma FSH level of >40IU/L.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects meeting any of the following criteria will be excluded from entry into or continuation in the study unless sponsor approval is obtained:
- •1. Smokers who report cigarette use of = 5 cigarette per day. Smoking will not be allowed on the days of each dosing up to the last blood sampling or the last assessment.
- •2. Use of any prescription drugs or over-the-counter (OTC) medication (vitamins, herbal supplements, dietary supplements) started within the last month prior to screening. All concomitant medication must be taken at a stable dose throughout the study. Paracetamol is acceptable as on/off treatment, but must be documented in the Concomitant medications/Significant non-drug therapies page of the CRF.
- •3. Participation in any clinical investigation within 4 weeks prior to dosing, or less than 10 times the corresponding half life of the drug taken, whichever is longer, or longer if required by local regulations, and for any other limitation of participation based on local regulations.
研究者
相似试验
进行中（未招募）
不适用
A single centre, randomised, partially-blind, placebo-controlled 3 way crossover pilot study investigating efficacy in terms of heartburn relief after taking (2x250mg) Gaviscon® chewable tablets, (1x20mg) Losec® MUPS® tablet and (2x) Placebo tablets in subjects with heartburn following a refluxogenic meal. - Three-period crossover pilot study in healthy subjects susceptible to heartburn.Investigating efficacy in terms of heatburn relief in healthy subjects following a refluxogenic meal.EUCTR2010-019414-24-GBReckitt Benckiser Healthcare (UK) Ltd
进行中（未招募）
不适用
A single-centre randomised, partially blind, single dose, crossover pilot study investigating the use of stopwatches to assess the onset of action of soothing and cooling of Gaviscon Peppermint Liquid, Double Action Gaviscon Liquid, Gaviscon Advance Liquid and a control in subjects with heartburn following a refluxogenic meal.Symptoms of heartburnEUCTR2007-005821-31-GBReckitt Benckiser Healthcare UK) Limited
进行中（未招募）
不适用
A single-centre randomised, partially blind, single dose, crossover study investigating the onset of action of soothing and cooling after taking Gaviscon Peppermint liquid, Double Action Gaviscon liquid, Gaviscon Instants Oral Powder, compared to a control in subjects with heartburn following a refluxogenic meal, using the 2-stopwatch technique - Gaviscon Soothing and CoolingSymptoms of heartburnEUCTR2008-006413-25-GBReckitt Benckiser Healthcare (UK) Limited
已完成
不适用
Study for safety and efficacy of Eicosapentaenoic acid in adult human male and female subjects with abdominal obesity.CTRI/2013/12/004220Parry Neutraceuticals18
已完成
1 期
A Single Center, Randomized, Double-Blind, Single-Dose, 2-Way Crossover, Dose Escalation Study of the Pharmacokinetics and Pharmacodynamics of PX811019 Compared with triethylenetetramine dihydrochloride in Normal Healthy VolunteersACTRN12612000738820Protemix Corporation24